A reusable, medical-grade silicone treatment tool designed to help optimize topical skincare performance around the eyes and smile lines

United States, 22nd Oct 2026 – TOPICAL SKIN, a leader in clean dermaceutical skincare, announces the launch of its Eye & Smile Reusable Silicone Patches Expression Line HydraLock. Designed for the areas most affected by daily facial movement, these reusable silicone patches help lock in topical treatments, support epidermal hydration, and visibly smooth the look of fine lines and creasing over time.

Made from soft, flexible, medical-grade silicone, the HydraLock patches comfortably hug the periorbital and perioral areas—including the under-eye region and smile or laugh lines. When applied over an appropriate serum or cream, the patches create a moisture-sealing, occlusive barrier that helps minimize moisture loss and supports prolonged contact between the skin and the user’s chosen treatment product.
The result is a simple yet elevated way to help enhance the performance of existing skincare while addressing the visible impact of dehydration, repetitive facial expressions, and mechanical compression in areas prone to early creasing.

“Some of the most visible expression lines occur in areas where the skin is constantly moving, folding, and experiencing repeated mechanical stress,” said Ewelina Aiossa, Founder of TOPICAL SKIN. “The Expression Line HydraLock patches were developed as a reusable skincare tool that works alongside the formulas consumers already love—helping create a more hydrated, smoother-looking appearance in precisely targeted zones.”
Unlike disposable under-eye masks and single-use treatment patches, Eye + Smile Reusable Silicone Patches are designed for repeated use, offering a more sustainable addition to a skincare routine without requiring consumers to replace their favorite targeted eye or line treatments.

Designed to Enhance Every Routine
Expression Line HydraLock patches are intended to be used with compatible eye creams, serums, moisturizers, or targeted treatments. By helping create an occlusive environment, the patches support epidermal hydration and can help improve the visible smoothness of the skin’s surface with consistent use.

Key benefits include:
    ● Helps reduce the appearance of fine lines and creasing around the eyes and smile area with consistent use.
    ● Helps visibly improve skin smoothness and hydration in targeted areas when used with an appropriate topical treatment.
    ● Creates a moisture-sealing barrier designed to enhance the effectiveness of serums and creams.
    ● Targets the under-eye area, smile lines, laugh lines, and nasolabial folds—zones commonly affected by repetitive expression and facial movement.
    ● Made with soft, flexible medical-grade silicone for a comfortable, contour-hugging fit.
    ● Reusable design helps replace dozens of single-use masks and patches.

The launch reflects TOPICAL SKIN’s continued commitment to practical, science-led skincare solutions that connect skin biology, ingredient performance, and everyday consumer use. Rather than positioning a patch as a replacement for skincare, HydraLock patches are designed to complement and amplify the user’s existing regimen.

How to Use
Apply a thin, even layer of a preferred serum, eye cream, moisturizer, or targeted treatment to clean skin. Place the patches over the under-eye and/or smile-line area, allowing the silicone to conform to the contours of the face. After use, gently remove, cleanse according to care instructions, and store for reuse. Eye + Smile Reusable Silicone Patches Expression Line HydraLock are now available at topicalskin.com.

About TOPICAL SKIN
TOPICAL SKIN is a science-focused skincare brand dedicated to creating high-performance, thoughtfully developed solutions for visible skin concerns. Rooted in a modern understanding of formulation, skin biology, and daily skin needs, the brand develops targeted products and tools designed to help consumers achieve healthier-looking, more resilient, and more radiant skin. TOPICAL SKIN’s ethos is grounded in cruelty-free, dermatologist-endorsed formulations designed for efficacy and sensorial enjoyment.

TOPICAL SKIN is available at topicalskin.com and through select professional and specialty retail partners across the United States, including dermatology clinics, plastic surgery offices, medical spas, and apothecaries. The brand is also available online at Ulta.com (https://www.ulta.com/brand/topical-skin), Nordstrom.com (https://www.nordstrom.com/brands/topical-skin–81036410), Macys.com (https://www.macys.com/shop/brands/topical-skin?id=406772), and other select retailers.

Media Contact

Organization: TOPICAL SKIN

Contact Person: Colleen Mathis Public Relations

Website: https://topicalskin.com/

Email: Send Email

Country: United States

Release id: 50088

View source version on King Newswire:
TOPICAL SKIN Clean Dermaceutical Brand Launches Medical-Grade Eye Smile Reusable Silicone Patches

The structural model and refined targeting methodology, combined with a focused infill drill program, are giving Selkirk the data needed to advance Feasibility Study work in the next phase of restart development at the Minto Project.

Canada, 22nd Oct 2026 – Global Stocks News – Sponsored content disseminated on behalf of Selkirk Copper Mines. On October 15, 2026, Selkirk Copper Mines (TSXV: SCMI) (FRA: IO20) (OTCQX: SKRKF) announced additional results from the Phase 2 drill program at the Minto Project in Yukon, Canada. 

Sixteen months ago, Selkirk First Nation (SFN) purchased the former Minto Mine out of bankruptcy, then partnered with the Frank Giustra-backed Fiore Group to form Selkirk Copper Mines.

A September 2026 Preliminary Economic Assessment (PEA) outlines a 13-year mine life at 4,100 tonnes per day (tpd), starting with underground mining, then adding two open pits later in the mine life.

The structural model and refined targeting methodology, combined with a focused infill drill program, are giving Selkirk the data needed to advance Feasibility Study work in the next phase of restart development at the Minto Project. 

“These results, notably the high grade and thick intercepts at Minto North, Copper Keel, and Area 118, underpin our confidence in the continuity and grade within the zones of mineralization that will improve the quality of our updated mineral resource modeling,” stated Colin Joudrie, Selkirk President & CEO, in the October 15, 2026 press release.

“This increases the potential in our integrated mine planning efforts to deliver higher grade material to the mill, resulting in higher metal contained in concentrate. I look forward to continued positive results from the Phase 2 campaign over the next 8-10 weeks and another updated mineral resource estimate (MRE) in Q1 2027.” 

Above: Plan view of the Minto Mine Property showing surface projections of mineralized zones as well as Phase 1 and Phase 2 drill collars. Drill hole results presented in this release are highlighted.

2026 Phase 2 Drill Program

The Phase 2 drill program targeted 50,000 metres and focused on expansion, exploration, and infill drilling in key target areas. The geo team identified opportunities to complete additional metres while staying on schedule and on budget.

In the September 26, 2026 YouTube Crux Investor Interview below, Selkirk Copper CEO Colin Joudrie explains how a favourable PEA supports a fast-tracked restart plan for the Minto Project in the Yukon.

“We are Canada’s first publicly traded mining company with a majority equity interest held by a First Nation,” Joudrie told Crux Investor. “The Selkirk First Nation (SFN) own 18% of the company. They have put a great amount of trust in us. They want this mine to go into production. I’m comfortable that we are doing the right things, but I don’t want anyone to think it’s easy. We need to work at this key relationship, continually over the life of this operation and into the future.”

“We’ve been able to drill over 105,000 meters in the last 12 months on an asset that hasn’t seen a drill turn on it in four years. Selkirk Copper has a team of mine-builders that can get it done. The global copper market is short copper. It’s very short on the quality of copper concentrate we can produce, about 38% copper. That’s pretty rare.”

“We’re leveraging over $330 million of above-ground investment by prior operators,” continued Joudrie. “Our team is pleased with the results of the recent PEA. It has flagged things that we should improve on. That’s part of the study. But it’s given us full confidence that we can move forward with a 13-year mine life, which is the longest mine life this asset has ever had.”

“We’re happy with the PEA economics,” Scott Fulton, Selkirk VP of Engineering, confirmed to Guy Bennett, CEO of Global Stocks News (GSN). “Our engineers and mine planners have been working collaboratively throughout the PEA with a team of engineering consultants hired independently by The Selkirk First Nation.”

“This is a robust, complete and comprehensive review of all aspects of the mine design, processing plant and infrastructure engineering,” added Fulton. “All costs have been built up from first principles over the Capex, Opex and Susex periods. Certain pre-capex costs are not included in the PEA economic model. We estimate these costs to be about $20 million.”

Because of key operational and financial variables, the SCMI PEA baseline economics are conservative.  For instance, the headline Net Present Value (NPV) number (C$494 million) is based on a copper “planning price” of $5.00/lb.

At the current copper price of US$6.50/lb, the after-tax NPV more than doubles to C$1.023 billion. Consensus copper price projections indicate a long-term upward trend, driven by green energy electrification, AI data centre demand and mine-supply deficits. A hypothetical $1/lb increase to $7.50/lb adds another $362 million to the projected NPV.

“The PEA confirms that we have a pathway to put the Minto Mine back into production, with a low capital expenditure (capex),” added Fulton. “A 13-year mine plan is a good start. There is potential to the north and south of the Minto Mine that I believe could turn this into a multi-decade project.”

Note: readers are cautioned that the PEA is preliminary in nature and includes Inferred Mineral Resources that are considered too speculative geologically to have economic considerations applied that would enable these resources to be categorized as Mineral Reserves. There is no certainty that the projections in the PEA will be realized. Mineral Resources which are not Mineral Reserves do not have demonstrated economic viability.

As of October 14, 2026, 54,711 metres of drilling have been completed in 223 drill holes, representing 109% of the planned meterage. The drill program is nearing completion. All geological logging, core cutting, and sample shipping are expected to be complete by early November.

Technical aspects of this release have been reviewed, verified and approved by Leif Bailey, P.Geo., Director of Geoscience & Exploration of Selkirk Copper Mines Inc., who is a qualified person as defined by National Instrument 43-101 – Standards of Disclosure for Mineral Projects. 

Disclaimer: Selkirk Copper Mines paid GSN C$1,750 for the research, creation and dissemination of this content.

Contact: guy.bennett@globalstocksnews.com

Full Disclaimer: Global Stocks News (GSN) researches and fact-checks diligently, but we cannot ensure our publications are free from error. Investing in publicly traded stocks is speculative and carries a high degree of risk. GSN makes no recommendation to purchase any individual stock. There may be forward-looking statements such as “project,” “anticipate,” “expect,” which are based on reasonable expectations, but these statements are imperfect predictors of future events. When compensation has been paid to GSN, the amount and nature of the compensation will be disclosed clearly.

Media Contact

Organization: Global Stocks News

Contact Person: guy.bennett@globalstocksnews.com

Website: https://www.globalstocksnews.com

Email: Send Email

Country: Canada

Release id: 50083

View source version on King Newswire:
Selkirk Copper Phase 2 Drill Program Returns High-Grade Intercepts At Minto North, Copper Keel, and Area 118

Hannover, Germany, October 21st, 2026, FinanceWire

Italian-built NexCut helps sheet metal shops tell a settings problem from a machine fault, and gives newer operators a guided way to learn what veterans know.

NexFabric today presented NexCut in Europe for the first time, at EuroBLECH 2026 on the stand of Esautomotion (Euronext Growth Milan: ESAU), Hall 15, Stand E28, after a first showing at CIIF in Shanghai. NexCut is the first laser-cutting application of the NexFabric industrial AI platform. Built in Italy, it pairs AI-assisted analysis with checks the operator confirms, so manufacturing teams can diagnose production problems without handing the decision to the machine.

Factories are losing the people who know their machines best. In Germany, 12.9 million workers, close to 30% of the workforce, will reach retirement age by 2036, according to the Federal Statistical Office. In Italy, companies reported difficulty filling 47.8% of planned hires, with CNC operators and welders among the hardest roles to fill, according to a CGIA analysis of Unioncamere Excelsior data. NexCut is built for that handover. A junior operator learns the diagnostic routine on the job, guided step by step, instead of spending years picking it up beside a veteran. Every diagnosis is saved as a procedure the next shift can reuse.

NexCut addresses a practical challenge in laser cutting: telling a problem with process settings from an issue with the machine or its hardware. Take a common case. Dross starts building on the underside of the parts. A less experienced operator may slow the cut or raise gas pressure. If the real cause is a dirty lens or a worn nozzle, that change wastes material and the fault stays. NexCut has the operator check the hardware first and confirm what they find. If there’s a hardware problem, it won’t clear the machine to run until it’s fixed.

Here’s how it works. Each laser cutter gets its own NexCut kit: a touchscreen operator station at the machine and a connected hardware module that brings in process signals from the cutter. When cut quality drops, NexCut combines those signals with physical checks the operator carries out and confirms, covering the lens, gas, focus position, cutting height, nozzle and machine stability. It narrows down the likely cause, explains why, and points to the fix. The operator makes the call. Every step is logged, so the process stays traceable and repeatable, and a central dashboard gives production managers a view across all connected machines.

“Running a laser cutter well takes years of experience, and even experienced operators still make mistakes,” said Stefano D’Andria, CEO & Founder of NexFabric. “NexCut is there to help and teach. Any operator can use it, whatever their experience, and the decision always stays with the person at the machine.”

The first proof of concept is running under real operating conditions at Soluzioni Markaurelio S.r.l. in Avezzano, Italy. It is testing NexCut against clear targets: an average guided diagnosis of 7 to 11 minutes, a 50 to 70% reduction in setup time, startup scrap and machine stoppages, and new operators working on their own within two to four weeks.

NexCut is built for manufacturers across Europe that run laser cutters. Operators get step-by-step guidance at the machine. Owners keep the know-how in-house when experienced staff leave. NexFabric plans to work with multiple industrial partners and dealers, broadening access while preserving manufacturer choice.

“Industrial AI must increase human decision-making capability, not replace it,” D’Andria added. “We’re starting in Italy, where our R&D is, and building for factories across Europe.”

D’Andria is at EuroBLECH through October 23 and available for interviews at the stand. To book a time, contact Orian Tal at orian@thepitch.media.

Manufacturers, dealers and technology partners can learn more at https://nexcut.ai or contact info@nexfabric.ai.

About NexFabric

NexFabric is an industrial AI platform built in Italy. It connects manufacturing processes and human expertise through guided diagnosis and human verification. Its first application, NexCut, focuses on laser cutting. Learn more at https://nexfabric.ai.

Contact

Orian Tal
The Pitch
orian@thepitch.media

Hannover, Germany, October 21st, 2026, FinanceWire

Italian-built NexCut helps sheet metal shops tell a settings problem from a machine fault, and gives newer operators a guided way to learn what veterans know.

NexFabric today presented NexCut in Europe for the first time, at EuroBLECH 2026 on the stand of Esautomotion (Euronext Growth Milan: ESAU), Hall 15, Stand E28, after a first showing at CIIF in Shanghai. NexCut is the first laser-cutting application of the NexFabric industrial AI platform. Built in Italy, it pairs AI-assisted analysis with checks the operator confirms, so manufacturing teams can diagnose production problems without handing the decision to the machine.

Factories are losing the people who know their machines best. In Germany, 12.9 million workers, close to 30% of the workforce, will reach retirement age by 2036, according to the Federal Statistical Office. In Italy, companies reported difficulty filling 47.8% of planned hires, with CNC operators and welders among the hardest roles to fill, according to a CGIA analysis of Unioncamere Excelsior data. NexCut is built for that handover. A junior operator learns the diagnostic routine on the job, guided step by step, instead of spending years picking it up beside a veteran. Every diagnosis is saved as a procedure the next shift can reuse.

NexCut addresses a practical challenge in laser cutting: telling a problem with process settings from an issue with the machine or its hardware. Take a common case. Dross starts building on the underside of the parts. A less experienced operator may slow the cut or raise gas pressure. If the real cause is a dirty lens or a worn nozzle, that change wastes material and the fault stays. NexCut has the operator check the hardware first and confirm what they find. If there’s a hardware problem, it won’t clear the machine to run until it’s fixed.

Here’s how it works. Each laser cutter gets its own NexCut kit: a touchscreen operator station at the machine and a connected hardware module that brings in process signals from the cutter. When cut quality drops, NexCut combines those signals with physical checks the operator carries out and confirms, covering the lens, gas, focus position, cutting height, nozzle and machine stability. It narrows down the likely cause, explains why, and points to the fix. The operator makes the call. Every step is logged, so the process stays traceable and repeatable, and a central dashboard gives production managers a view across all connected machines.

“Running a laser cutter well takes years of experience, and even experienced operators still make mistakes,” said Stefano D’Andria, CEO & Founder of NexFabric. “NexCut is there to help and teach. Any operator can use it, whatever their experience, and the decision always stays with the person at the machine.”

The first proof of concept is running under real operating conditions at Soluzioni Markaurelio S.r.l. in Avezzano, Italy. It is testing NexCut against clear targets: an average guided diagnosis of 7 to 11 minutes, a 50 to 70% reduction in setup time, startup scrap and machine stoppages, and new operators working on their own within two to four weeks.

NexCut is built for manufacturers across Europe that run laser cutters. Operators get step-by-step guidance at the machine. Owners keep the know-how in-house when experienced staff leave. NexFabric plans to work with multiple industrial partners and dealers, broadening access while preserving manufacturer choice.

“Industrial AI must increase human decision-making capability, not replace it,” D’Andria added. “We’re starting in Italy, where our R&D is, and building for factories across Europe.”

D’Andria is at EuroBLECH through October 23 and available for interviews at the stand. To book a time, contact Orian Tal at orian@thepitch.media.

Manufacturers, dealers and technology partners can learn more at https://nexcut.ai or contact info@nexfabric.ai.

About NexFabric

NexFabric is an industrial AI platform built in Italy. It connects manufacturing processes and human expertise through guided diagnosis and human verification. Its first application, NexCut, focuses on laser cutting. Learn more at https://nexfabric.ai.

Contact

Orian Tal
The Pitch
orian@thepitch.media

Boca Raton, Florida, October 21st, 2026, FinanceWire

• Final pre-MAA package submitted to MHRA on October 20, 2026
• Full MAA submission targeted for early February 2027, under a revised strategy that could bring potential UK approval forward by approximately six weeks
• US BLA expected to be submitted in Q2, 2027

INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced that it has submitted its final pre-Marketing Authorisation Application (pre-MAA) package to the UK Medicines and Healthcare products Regulatory Agency (MHRA) for Ebstrocel (CORDStrom), its investigational cell therapy for recessive dystrophic epidermolysis bullosa (RDEB). The company has revised prior guidance to indicate that faster-than-expected manufacturing progress supports a full MAA submission in early February 2027, with potential UK approval in mid-2027, subject to MHRA review.

Following MHRA feedback on the final pre-MAA package, INmune Bio plans to finalize and submit a complete application in February, 2027, replacing the sequential rolling submission previously planned to begin in late 2026. Based on progress in chemistry, manufacturing and controls (CMC) and discussions with regulatory advisors, the Company believes this approach could accelerate potential UK approval by approximately six weeks from prior guidance.

The Company anticipates an MHRA response within three to six months after submission, subject to application validation, agency review and any requests for additional information. Submission of the complete package is intended to support assessment of the clinical, manufacturing and quality data together.

“This is a remarkable achievement by the whole CMC team and our external regulatory advisors allowing us to accelerate the potential approval for Ebstrocel for children with RDEB,” said Mark Lowdell, Chief Scientific Officer of INmune Bio. “Our progress allows us to bring forward the anticipated timeline to commercial supply, subject to approval, for children and families waiting for treatment.”

In parallel, INmune Bio has engaged U.S. regulatory advisors with rare disease expertise to prepare and submit a Type B meeting request to the U.S. Food and Drug Administration (FDA). Subject to feedback from that meeting, the Company plans to submit a Biologics License Application (BLA) in the second quarter of 2027, seeking traditional or accelerated approval, as appropriate.

“Based on positive feedback from our regulatory consultants in the U.S, we are prioritizing our FDA application ahead of an EMA submission, building on Ebstrocel’s U.S. Orphan Drug and Rare Pediatric Disease designations,” said David Moss, Chief Executive Officer of INmune Bio. “With potential UK and U.S. approvals in 2027, we are approaching a pivotal year. Approval in either or both markets would mark a major milestone for INmune Bio and bring Ebstrocel closer to patients and families living with RDEB.”

About INmune Bio Inc.

INmune Bio Inc. is a publicly traded (NASDAQ: INMB), late-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. The Company’s clinical-development strategy centers on advanced precision medicine, matching drug mechanisms directly to patient biology to optimize clinical outcomes.

INmune Bio is actively advancing two late-stage product platforms toward registrational milestones:

• CORDStrom: A proprietary, pooled, allogeneic, human umbilical cord-derived mesenchymal stromal cell platform engineered to address the historical clinical challenges of donor variability and manufacturing inconsistency. Following successful clinical readouts in RDEB, the platform is transitioning to regulatory filing phases, with an MAA planned for the UK MHRA in 2026 and EU EMA in 2027, alongside a planned U.S. Biologics License Application (BLA) submission.
• XPro1595: A Dominant-Negative Tumor Necrosis Factor (DN-TNF) platform designed to selectively neutralize soluble TNF (sTNF) and reduce neuroinflammation without compromising protective immune function. Backed by recently granted FDA Fast Track designation and successful regulatory alignment from an End-of-Phase 2 meeting, XPro1595 is positioned for an integrated Phase 2b/3 seamless adaptive registrational program in neuroinflammation-enriched early Alzheimer’s disease.

To learn more about INmune Bio’s pipeline and its approach to harnessing the innate immune system, please visit www.inmunebio.com.

Forward Looking Statements

The Company’s product candidates remain in clinical development stage and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release related to the development or commercialization of product candidates and other business and financial matters, including without limitation, trial results and data, including Ebstrocel, XPro and INKmune trial results, timing of key milestones, future plans or expectations, and the prospects for receiving regulatory approval or commercializing or selling any product or drug candidates, may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to several risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements because of these risks and uncertainties. CORDStrom, XPro1595 (XPro, pegipanermin), and INKmune have either finished clinical trials, are still in clinical trials or are preparing to start clinical trials and have not been approved by the US Food and Drug Administration (FDA), the UK MHRA or any regulatory body and there cannot be any assurance that they will be approved by the FDA, the UK MHRA or any regulatory body or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements to reflect any event or circumstance that may arise after the date of this release.

INmune Bio Contacts:

David Moss

Chief Executive Officer

(561) 710-0512

info@inmunebio.com

Contact

Head of Investor Relations
Daniel Carlson
dcarlson@inmunebio.com
(415) 509-4590

New York, USA, October 21st, 2026, FinanceWire

The rulebook consolidates account requirements, removes three funded account restrictions and maintains transparent change logs so traders can track rule updates.

Hola Prime, a global proprietary trading firm, today announced the launch of The Rulebook, a consolidated rulebook designed to make trading rules and account conditions easier to access, understand and track.

The updated rulebook brings key information covering challenge passing criteria, conditions, trading rules, breach conditions and account requirements into one place. It also maintains transparent change logs, allowing traders to follow updates to the rules and understand how the firm’s requirements evolve over time.

By centralising this information, Hola Prime aims to give traders a clearer reference point throughout their trading journey, from understanding account conditions before trading to reviewing the rules that apply to their accounts.

All Rules in One Place, With Transparent Change Logs

Prop trading rules and account conditions play an important role in how traders manage their accounts. Having access to the applicable requirements in one place helps traders understand their obligations without having to navigate multiple resources.

The Rulebook brings these requirements together in a single document, giving traders one central reference for the rules governing their accounts. The rulebook is designed to make access to information more straightforward and give traders greater clarity on the requirements they are expected to follow.

Three Restrictions Removed

As part of the update, Hola Prime has removed three restrictions that previously applied to funded accounts:

• The 60% maximum concentration per trade
• The 70% maximum margin rule
• The three-minute Stop Loss deadline

These changes form part of Hola Prime’s broader effort to simplify its trading conditions while making the applicable rules easier for traders to review.

A Clearer Process for Breach Appeals

While The Rulebook provides a central reference for trading rules and account conditions, Hola Prime also offers traders a way to challenge a breach they believe has been applied incorrectly.

Traders who have grounds to dispute a breach can submit an appeal through the available appeal process. Hola Prime’s Risk Team reviews the circumstances and provides a written explanation of the outcome, whether the original breach is upheld or reversed.

This process gives traders a formal channel to raise concerns and seek clarification when they believe an account decision does not align with the applicable rules.

Making Rule Transparency Part of the Trader Experience

Somesh Kapuria, CEO of Hola Prime, said: “Clear rules are an important part of a fair trading environment. Traders should be able to find the conditions that apply to their accounts without having to search across multiple resources. With The Rulebook, we are bringing those requirements together and maintaining transparent change logs so traders can keep track of updates. We have also removed three restrictions from Sim. funded accounts as part of our ongoing effort to make our trading conditions clearer and more straightforward.”

The Rulebook is available to Hola Prime traders on the official Hola Prime website.

About Hola Prime

Hola Prime is a global proprietary trading firm offering funded trading accounts to traders worldwide. The firm provides access to trading opportunities across major financial instruments, including forex, commodities and indices, with programs designed for different trading approaches.

Known for its 1-Hour Payout model, Hola Prime has received industry recognition, including the Global Most Transparent Prop Firm 2025 award by Finance Magnates and the Fastest Payout Prop Firm MEA 2026 award by UF Awards.

For more information, users can visit www.holaprime.com.

Contact

Manya Bhardwaj
HolaPrime
contactus@holaprime.com

Boca Raton, Florida, October 21st, 2026, FinanceWire

• Final pre-MAA package submitted to MHRA on October 20, 2026
• Full MAA submission targeted for early February 2027, under a revised strategy that could bring potential UK approval forward by approximately six weeks
• US BLA expected to be submitted in Q2, 2027

INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced that it has submitted its final pre-Marketing Authorisation Application (pre-MAA) package to the UK Medicines and Healthcare products Regulatory Agency (MHRA) for Ebstrocel (CORDStrom), its investigational cell therapy for recessive dystrophic epidermolysis bullosa (RDEB). The company has revised prior guidance to indicate that faster-than-expected manufacturing progress supports a full MAA submission in early February 2027, with potential UK approval in mid-2027, subject to MHRA review.

Following MHRA feedback on the final pre-MAA package, INmune Bio plans to finalize and submit a complete application in February, 2027, replacing the sequential rolling submission previously planned to begin in late 2026. Based on progress in chemistry, manufacturing and controls (CMC) and discussions with regulatory advisors, the Company believes this approach could accelerate potential UK approval by approximately six weeks from prior guidance.

The Company anticipates an MHRA response within three to six months after submission, subject to application validation, agency review and any requests for additional information. Submission of the complete package is intended to support assessment of the clinical, manufacturing and quality data together.

“This is a remarkable achievement by the whole CMC team and our external regulatory advisors allowing us to accelerate the potential approval for Ebstrocel for children with RDEB,” said Mark Lowdell, Chief Scientific Officer of INmune Bio. “Our progress allows us to bring forward the anticipated timeline to commercial supply, subject to approval, for children and families waiting for treatment.”

In parallel, INmune Bio has engaged U.S. regulatory advisors with rare disease expertise to prepare and submit a Type B meeting request to the U.S. Food and Drug Administration (FDA). Subject to feedback from that meeting, the Company plans to submit a Biologics License Application (BLA) in the second quarter of 2027, seeking traditional or accelerated approval, as appropriate.

“Based on positive feedback from our regulatory consultants in the U.S, we are prioritizing our FDA application ahead of an EMA submission, building on Ebstrocel’s U.S. Orphan Drug and Rare Pediatric Disease designations,” said David Moss, Chief Executive Officer of INmune Bio. “With potential UK and U.S. approvals in 2027, we are approaching a pivotal year. Approval in either or both markets would mark a major milestone for INmune Bio and bring Ebstrocel closer to patients and families living with RDEB.”

About INmune Bio Inc.

INmune Bio Inc. is a publicly traded (NASDAQ: INMB), late-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. The Company’s clinical-development strategy centers on advanced precision medicine, matching drug mechanisms directly to patient biology to optimize clinical outcomes.

INmune Bio is actively advancing two late-stage product platforms toward registrational milestones:

• CORDStrom: A proprietary, pooled, allogeneic, human umbilical cord-derived mesenchymal stromal cell platform engineered to address the historical clinical challenges of donor variability and manufacturing inconsistency. Following successful clinical readouts in RDEB, the platform is transitioning to regulatory filing phases, with an MAA planned for the UK MHRA in 2026 and EU EMA in 2027, alongside a planned U.S. Biologics License Application (BLA) submission.
• XPro1595: A Dominant-Negative Tumor Necrosis Factor (DN-TNF) platform designed to selectively neutralize soluble TNF (sTNF) and reduce neuroinflammation without compromising protective immune function. Backed by recently granted FDA Fast Track designation and successful regulatory alignment from an End-of-Phase 2 meeting, XPro1595 is positioned for an integrated Phase 2b/3 seamless adaptive registrational program in neuroinflammation-enriched early Alzheimer’s disease.

To learn more about INmune Bio’s pipeline and its approach to harnessing the innate immune system, please visit www.inmunebio.com.

Forward Looking Statements

The Company’s product candidates remain in clinical development stage and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release related to the development or commercialization of product candidates and other business and financial matters, including without limitation, trial results and data, including Ebstrocel, XPro and INKmune trial results, timing of key milestones, future plans or expectations, and the prospects for receiving regulatory approval or commercializing or selling any product or drug candidates, may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to several risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements because of these risks and uncertainties. CORDStrom, XPro1595 (XPro, pegipanermin), and INKmune have either finished clinical trials, are still in clinical trials or are preparing to start clinical trials and have not been approved by the US Food and Drug Administration (FDA), the UK MHRA or any regulatory body and there cannot be any assurance that they will be approved by the FDA, the UK MHRA or any regulatory body or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements to reflect any event or circumstance that may arise after the date of this release.

INmune Bio Contacts:

David Moss

Chief Executive Officer

(561) 710-0512

info@inmunebio.com

Contact

Head of Investor Relations
Daniel Carlson
dcarlson@inmunebio.com
(415) 509-4590

New York, USA, October 21st, 2026, FinanceWire

The rulebook consolidates account requirements, removes three funded account restrictions and maintains transparent change logs so traders can track rule updates.

Hola Prime, a global proprietary trading firm, today announced the launch of The Rulebook, a consolidated rulebook designed to make trading rules and account conditions easier to access, understand and track.

The updated rulebook brings key information covering challenge passing criteria, conditions, trading rules, breach conditions and account requirements into one place. It also maintains transparent change logs, allowing traders to follow updates to the rules and understand how the firm’s requirements evolve over time.

By centralising this information, Hola Prime aims to give traders a clearer reference point throughout their trading journey, from understanding account conditions before trading to reviewing the rules that apply to their accounts.

All Rules in One Place, With Transparent Change Logs

Prop trading rules and account conditions play an important role in how traders manage their accounts. Having access to the applicable requirements in one place helps traders understand their obligations without having to navigate multiple resources.

The Rulebook brings these requirements together in a single document, giving traders one central reference for the rules governing their accounts. The rulebook is designed to make access to information more straightforward and give traders greater clarity on the requirements they are expected to follow.

Three Restrictions Removed

As part of the update, Hola Prime has removed three restrictions that previously applied to funded accounts:

• The 60% maximum concentration per trade
• The 70% maximum margin rule
• The three-minute Stop Loss deadline

These changes form part of Hola Prime’s broader effort to simplify its trading conditions while making the applicable rules easier for traders to review.

A Clearer Process for Breach Appeals

While The Rulebook provides a central reference for trading rules and account conditions, Hola Prime also offers traders a way to challenge a breach they believe has been applied incorrectly.

Traders who have grounds to dispute a breach can submit an appeal through the available appeal process. Hola Prime’s Risk Team reviews the circumstances and provides a written explanation of the outcome, whether the original breach is upheld or reversed.

This process gives traders a formal channel to raise concerns and seek clarification when they believe an account decision does not align with the applicable rules.

Making Rule Transparency Part of the Trader Experience

Somesh Kapuria, CEO of Hola Prime, said: “Clear rules are an important part of a fair trading environment. Traders should be able to find the conditions that apply to their accounts without having to search across multiple resources. With The Rulebook, we are bringing those requirements together and maintaining transparent change logs so traders can keep track of updates. We have also removed three restrictions from Sim. funded accounts as part of our ongoing effort to make our trading conditions clearer and more straightforward.”

The Rulebook is available to Hola Prime traders on the official Hola Prime website.

About Hola Prime

Hola Prime is a global proprietary trading firm offering funded trading accounts to traders worldwide. The firm provides access to trading opportunities across major financial instruments, including forex, commodities and indices, with programs designed for different trading approaches.

Known for its 1-Hour Payout model, Hola Prime has received industry recognition, including the Global Most Transparent Prop Firm 2025 award by Finance Magnates and the Fastest Payout Prop Firm MEA 2026 award by UF Awards.

For more information, users can visit www.holaprime.com.

Contact

Manya Bhardwaj
HolaPrime
contactus@holaprime.com